• VLP Therapeutics gets $3.9 million grant from GHIT to further develop dengue vaccine

    • December 15, 2018
    • Posted By : admin
    • 0 Comment

    The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a $3.9 million grant to further develop a novel tetravalent dengue virus-like particle vaccine.

    “The GHIT Fund’s commitment is an important step for the further validation of our virus-like particle vaccine technology. We are grateful to the GHIT Fund for its continued support of this important vaccine. Their past support years enabled us to show proof of concept for our novel dengue VLP vaccine in critical animal studies, and the new grant will enable further development and manufacturing of this novel Dengue vaccine candidate, says Dr Wataru Akahata, CEO of VLP Therapeutics.

    VLP Therapeutics has developed a novel dengue VLP vaccine using its proprietary technology. VLP Therapeutics’ previously funded GHIT project demonstrated the dengue VLP vaccine’s efficacy and safety in preclinical studies including non-human primates. The current project is focused on producing this VLP vaccine to conduct clinical trials. VLP Therapeutics is partnering with The Japan National Institute of Infectious Disease, Nagasaki University, Latham Biopharm Group and the Johns Hopkins University Bloomberg School of Public Health.


You Might Also Like

No comments found



error: Content is protected !!